• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝素治疗:一项随机前瞻性研究。

Heparin therapy: a randomized prospective study.

作者信息

Wilson J R, Lampman J

出版信息

Am Heart J. 1979 Feb;97(2):155-8. doi: 10.1016/0002-8703(79)90349-1.

DOI:10.1016/0002-8703(79)90349-1
PMID:760446
Abstract

Eighty patients were assigned randomly either to continuous or to intermittent heparin therapy, with control by the Lee-White Clotting Time (LWCT). Major bleeding complications occurred in 7.5 per cent and minor complications in 18 per cent of the entire group. The incidence of major bleeding complications in the continuous group (5 per cent) did not differ significantly from the incidence in the intermittent group (10 per cent). In contrast, bleeding complications were significantly more frequent in patients with soft-tissue trauma due to such procedures as thoracenteses and cut-downs, vascular damage due to other causes, and LWCTs over 35 minutes for 2 consecutive days. The incidence of bleeding complications appear to be the same in patients receiving intermittent as in those receiving continuous heparin therapy. Thoracenteses, cut-downs, and other forms of soft-tissue injury predispose to bleeding complications while laboratory monitoring with the LWCT may help to reduce bleeding complications.

摘要

80名患者被随机分配接受持续或间歇肝素治疗,并通过李氏-怀特凝血时间(LWCT)进行监测。整个组中,严重出血并发症发生率为7.5%,轻微并发症发生率为18%。持续治疗组的严重出血并发症发生率(5%)与间歇治疗组(10%)相比,差异无统计学意义。相比之下,因胸腔穿刺和切开等操作导致软组织创伤、其他原因引起血管损伤以及连续两天LWCT超过35分钟的患者,出血并发症明显更频繁。接受间歇肝素治疗的患者与接受持续肝素治疗的患者出血并发症发生率似乎相同。胸腔穿刺、切开及其他形式的软组织损伤易引发出血并发症,而使用LWCT进行实验室监测可能有助于减少出血并发症。

相似文献

1
Heparin therapy: a randomized prospective study.肝素治疗:一项随机前瞻性研究。
Am Heart J. 1979 Feb;97(2):155-8. doi: 10.1016/0002-8703(79)90349-1.
2
Randomized prospective trial of continuous vs intermittent heparin therapy.
JAMA. 1976 Sep 20;236(12):1365-7.
3
Haemorrhagic complications of heparin therapy.肝素治疗的出血并发症。
Lancet. 1977 May 28;1(8022):1133-5. doi: 10.1016/s0140-6736(77)92388-1.
4
Heparin therapy in venous thromboembolism.
Am J Med. 1981 Apr;70(4):808-16. doi: 10.1016/0002-9343(81)90537-4.
5
Management of heparin therapy: Controlled prospective trial.肝素治疗的管理:对照前瞻性试验。
N Engl J Med. 1975 May 15;292(20):1046-50. doi: 10.1056/NEJM197505152922002.
6
Control and complications of intermittent heparin therapy.
Surg Gynecol Obstet. 1977 Sep;145(3):338-42.
7
Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.皮下注射达那肝素与静脉注射普通肝素治疗静脉血栓栓塞症的比较:一项随机对照试验。
Ann Intern Med. 1995 Jul 1;123(1):1-9. doi: 10.7326/0003-4819-123-1-199507010-00001.
8
Anticoagulant treatment of thromboembolism with intravenous heparin therapy in the early postoperative period following total joint arthroplasty.全关节置换术后早期采用静脉肝素治疗对血栓栓塞进行抗凝治疗。
J Bone Joint Surg Am. 2000 Feb;82(2):207-12. doi: 10.2106/00004623-200002000-00006.
9
Laboratory control of heparin therapy.肝素治疗的实验室监测
J Clin Pathol. 1971 Sep;24(6):542-6. doi: 10.1136/jcp.24.6.542.
10
Complications of heparin therapy after total joint arthroplasty.全关节置换术后肝素治疗的并发症
J Bone Joint Surg Am. 1989 Sep;71(8):1130-4.

引用本文的文献

1
Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin.低分子量肝素治疗静脉血栓栓塞症
J Thromb Thrombolysis. 1995;1(3):279-284. doi: 10.1007/BF01060737.
2
Intravenous heparin dosing: patterns and variations in internists' practices.静脉注射肝素给药:内科医生实践中的模式与差异。
J Gen Intern Med. 1993 Oct;8(10):536-42. doi: 10.1007/BF02599634.
3
Anticoagulants in older patients. A safety perspective.老年患者的抗凝剂。安全性视角。
Drugs Aging. 1995 Jan;6(1):45-54. doi: 10.2165/00002512-199506010-00004.
4
Risk of complications during intravenous heparin therapy.静脉注射肝素治疗期间的并发症风险。
West J Med. 1982 Mar;136(3):189-97.
5
Clinical pharmacokinetics of heparin.肝素的临床药代动力学
Clin Pharmacokinet. 1980 May-Jun;5(3):204-20. doi: 10.2165/00003088-198005030-00002.
6
The economics of general thromboembolic prophylaxis.普通血栓栓塞预防的经济学
World J Surg. 1988 Jun;12(3):349-55. doi: 10.1007/BF01655669.
7
[A fatality caused by heparin overdose].[一例肝素过量导致的死亡病例]
Z Rechtsmed. 1989;103(2):147-53. doi: 10.1007/BF01258919.
8
Heparin pharmacokinetics and pharmacodynamics.肝素的药代动力学和药效学。
Clin Pharmacokinet. 1992 May;22(5):359-74. doi: 10.2165/00003088-199222050-00003.
9
Heparin therapy. Regimens and treatment considerations.肝素治疗。方案及治疗注意事项。
Drugs. 1992 Nov;44(5):738-49. doi: 10.2165/00003495-199244050-00006.